Workflow
Biomedical Research
icon
Search documents
Cell Stem Cell:刘鹏/陈晓芳/杨帆团队开发类器官共培养模型,用于探究肺癌的系统性抗肿瘤免疫
生物世界· 2025-06-13 04:04
Core Viewpoint - The research emphasizes the importance of understanding the interaction between tumor microenvironment and systemic immune macroenvironment for developing more effective cancer diagnosis and treatment strategies [2]. Group 1: Research Development - A novel organoid co-culture model, the Gel-Liquid Interface (GLI) co-culture model, was developed to explore systemic anti-tumor immunity in lung cancer [3]. - The research team established a lung cancer organoid (LCO) paired with peripheral blood mononuclear cells (PBMC) using the GLI model, enhancing the interaction between immune cells and tumor organoids to better simulate systemic anti-tumor immune responses in vivo [4]. Group 2: Findings and Implications - The study demonstrated that the GLI model's response under anti-PD-1 (αPD1) treatment accurately reflects the immune treatment outcomes of corresponding lung cancer patients [5]. - Functional multi-omics analysis in the GLI model revealed various tumor immune processes mediated by T cells derived from PBMC, characterizing circulating tumor-reactive T cells with an effector memory-like phenotype (GNLY+ CD44+ CD9+) as potential indicators of immunotherapy effectiveness [6]. - Key findings indicate that the GLI co-culture model reflects the immune treatment outcomes of lung cancer patients, reveals the infiltration and activation of peripheral T cells post immune checkpoint inhibitor (ICI) treatment, and shows that PBMC-derived T cells transform into more cytotoxic tumor-reactive T cells under ICI influence [7]. Group 3: Overall Conclusion - Overall, the research results suggest that the GLI co-culture model can be utilized for developing diagnostic strategies for precision immunotherapy and aids in understanding its underlying mechanisms [9].
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Globenewswire· 2025-05-30 11:00
Core Insights - Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series to discuss advancements in the field of proteomics and its implications for healthcare [1] - The first session will focus on high-plex, high-quality proteomics, featuring insights from researchers involved in the EPIC cancer study [2] - Future sessions will cover various topics, including comparative metrics for proteomic platforms, deployment in biobanks, and the role of proteomics in accelerating drug development [3][4][5] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies aimed at enhancing biomedical research and drug development [7] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide reliable insights into health and disease [7] - Standard BioTools collaborates with academic, government, and clinical laboratories globally, focusing on critical areas in translational and clinical research [9]
Nautilus Biotechnology(NAUT) - 2025 Q1 - Earnings Call Transcript
2025-04-29 13:32
Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease from $21.6 million in Q1 2024, reflecting a focus on cost efficiency [29] - Research and development expenses decreased to $11.5 million from $12.9 million year-over-year [29] - General and administrative expenses were $7.3 million in Q1 2025 compared to $8.7 million in the prior year [30] - Overall net loss for Q1 2025 was $16.6 million, down from $18.7 million in the prior year [30] - The company ended the quarter with approximately $193 million in cash and equivalents, compared to $206 million at the end of 2024, projecting a cash runway through 2027 [31] Business Line Data and Key Metrics Changes - The company is advancing its tau proteoform assay and broad scale proteome assay, with significant progress in transitioning both towards readiness for larger scale applications [12][22] - The tau proteoform assay exceeded expectations in reproducibility and accuracy, with a median percent error of approximately 10% and a median coefficient of variation of 1.5% [16][17] - The platform demonstrated a dynamic range exceeding four orders of magnitude, significantly better than current methods [20] Market Data and Key Metrics Changes - There is significant interest from researchers in both targeted proteoform and broad scale discovery capabilities, with ongoing discussions with large pharma companies and academic institutions [10][11] - The company conducted in-depth interviews with over 30 proteomics researchers to understand customer segments and drivers of adoption [9] Company Strategy and Development Direction - The company aims to unlock the full potential of the proteome, focusing on targeted proteoform detection and broad scale discovery as significant untapped opportunities in biology [28] - The anticipated launch of the platform is planned for late 2026, with a focus on ensuring cash runway extends beyond that point [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made towards partnerships and the potential impact of their technology on neurodegenerative diseases [11][32] - The company is monitoring supply chain exposure to tariffs, with no current impact on sourcing materials and components [40][41] - Management emphasized the importance of customer feedback and ongoing research to refine their value proposition ahead of the commercial launch [61][62] Other Important Information - The company plans to submit a manuscript summarizing verification and validation work and biological pilot studies in the coming months [25] - The focus for 2025 is on demonstrating the capabilities of measuring complete intact protein proteoforms rather than immediate revenue generation [46] Q&A Session Summary Question: Update on Tau-related partnerships - Management confirmed ongoing discussions with partners in pharma and academic sectors, expecting to sign an initial partnership in the first half of 2025 [36] Question: Supply chain exposure to tariffs - Management stated they are monitoring the situation closely and have not seen any effects on sourcing materials or pricing [40][41] Question: Economics of targeted protein proteoform partnerships - Management indicated a range of potential business models is being explored, focusing on demonstrating the technology's capabilities rather than immediate revenue [44][46] Question: Milestones for converting partnership interests - Management explained the engagement process involves educating potential partners about the technology and aligning research interests [52] Question: Any blind spots impacting commercial launch - Management expressed confidence in understanding the work ahead and executing efficiently, with no significant blind spots identified [58]
Nautilus Biotechnology(NAUT) - 2025 Q1 - Earnings Call Transcript
2025-04-29 13:32
Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease from $21.6 million in Q1 2024, reflecting a focus on cost efficiency [28] - Research and development expenses decreased to $11.5 million from $12.9 million year-over-year [28] - General and administrative expenses were $7.3 million in Q1 2025 compared to $8.7 million in the prior year [29] - Overall net loss for Q1 2025 was $16.6 million, down from $18.7 million in the prior year [29] - Cash, cash equivalents, and investments at the end of the quarter totaled approximately $193 million, compared to $206 million at the end of 2024 [30] Business Line Data and Key Metrics Changes - The company is advancing its tau proteoform assay and broad scale proteome assay, with significant progress reported in transitioning these assays towards readiness for larger scale applications [11][12] - The tau proteoform assay exceeded expectations in reproducibility and accuracy, with a median percent error of approximately 10% and a median coefficient of variation of 1.5% [15][16] - The platform demonstrated a dynamic range exceeding four orders of magnitude, significantly better than current methods [19] Market Data and Key Metrics Changes - There is significant interest from customers and partners in the company's tau capabilities and targeted proteoform detection, with ongoing discussions with large pharma companies and academic institutions [9][10] - The company conducted in-depth interviews with over 30 proteomics researchers to understand customer segments and drivers of adoption, confirming strong interest in both targeted proteoform and broad scale discovery capabilities [8][9] Company Strategy and Development Direction - The company aims to unlock the full potential of the proteome, focusing on both targeted proteoform analysis and broad scale discovery as significant untapped opportunities in biology [27] - The anticipated launch of the platform is planned for late 2026, with a focus on ensuring cash runway extends well beyond that point [29][30] - The company is prioritizing partnerships that demonstrate the capabilities of measuring complete intact protein proteoforms at single molecule resolution [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made towards the launch of the platform and the positive feedback received from potential customers and partners [10][32] - The company is monitoring supply chain exposure closely, particularly regarding tariffs, but has not yet seen any significant impact on sourcing materials [40][41] - Management emphasized the importance of customer research and understanding market requirements to ensure a successful commercial launch [60][61] Other Important Information - The company reduced its headcount by approximately 16% to extend its cash runway and focus resources on key development milestones [29] - The verification and validation process for the tau assay was crucial for building confidence in the entire platform, as it shares core components with the broad scale proteome assay [58] Q&A Session Summary Question: Update on tau-related partnerships - Management confirmed ongoing discussions with partners in both pharma and academic sectors, expecting to sign an initial partnership in the first half of 2025 [36] Question: Supply chain exposure to tariffs - Management stated that they are monitoring the situation closely and have not yet seen any effects on sourcing materials or prices [40] Question: Economics of targeted protein proteoform partnerships - Management indicated that they are exploring a range of business models for partnerships, focusing on demonstrating the technology's capabilities rather than immediate revenue [44][46] Question: Milestones for converting partnership interests - Management explained that the initial phase involves educating potential partners about the technology, with excitement noted across all customer segments [52] Question: Potential blind spots impacting commercial launch - Management expressed confidence in their understanding of the work ahead and the importance of product reliability and market positioning for a successful launch [56][59]
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Newsfilter· 2025-04-24 11:00
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next- generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Associat ...
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
Globenewswire· 2025-04-22 11:00
Core Viewpoint - Standard BioTools Inc. is set to report its first quarter 2025 financial results on May 6, 2025, after market close, followed by a conference call to discuss these results and operational progress [1]. Company Overview - Standard BioTools Inc. (Nasdaq: LAB) offers a portfolio of next-generation technologies aimed at accelerating biomedical research and improving medicine development [3]. - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights into health and disease, facilitating better patient outcomes [3]. - Standard BioTools collaborates with various sectors including academic, government, pharmaceutical, and biotechnology research, focusing on critical areas in translational and clinical research like oncology and immunology [3].
Registration now Open: Europe Circulating Biomarkers Conference 2025 - Focus on EVs, cfDNA, CTCs, Circulating RNAs and Oncoproteins (Montpellier, France - June 24-25, 2025)
Globenewswire· 2025-03-25 09:41
Group 1 - The "Circulating Biomarkers Europe 2025" conference focuses on various classes of circulating biomarkers, including Extracellular Vesicles (EVs), Circulating Cell-Free DNA (cfDNA), Circulating Tumour Cells (CTCs), and Circulating RNAs and Oncoproteins [1][2] - The conference aims to provide a scientific perspective on technologies, tools, and biological investigations related to these biomarker classes, highlighting their insights into different biological processes [2] - Registered delegates will have access to co-located conference tracks, enhancing networking opportunities and business development [3] Group 2 - The agenda includes topics such as Liquid Biopsy Development for cfDNA and CTCs, emerging companies in the biomarker space, and diagnostic potential of EVs [7] - Notable speakers include experts from various research institutions and universities, emphasizing the conference's focus on cutting-edge research and development in the field [7]